Suppr超能文献

基于血细胞的炎症标志物作为结直肠癌早期诊断的有用工具

Blood-Cell-Based Inflammatory Markers as a Useful Tool for Early Diagnosis in Colorectal Cancer.

作者信息

Hernandez-Ainsa Maria, Velamazan Raul, Lanas Angel, Carrera-Lasfuentes Patricia, Piazuelo Elena

机构信息

Service of Digestive Diseases, University Clinic Hospital, Zaragoza, Spain.

Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.

出版信息

Front Med (Lausanne). 2022 Jun 20;9:843074. doi: 10.3389/fmed.2022.843074. eCollection 2022.

Abstract

BACKGROUND

Systemic inflammation seems to be involved in the pathogenetic pathways of colorectal cancer (CRC). Analytical markers that reflect the inflammatory status, such as neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) or systemic immune-inflammation index (SII), have been proposed as tools for the prognosis of CRC. Nevertheless, their use for diagnosis has been scarcely investigated.

AIMS

To analyze the ability of these markers and of a new marker combining SII and hemoglobin concentration, named NP/LHb = [neutrophils x platelets]/[lymphocytes x hemoglobin], as tools for CRC diagnosis. Furthermore, we studied their association with CRC-related variables.

METHODS

Case-control study including 214 CRC patients and 214 controls without CRC, matched by age (±5 years) and sex. We collected demographic, CRC-related and laboratory variables to calculate NLR, PLR, SII, and NP/LHb. In the case group, the laboratory variables were collected at two different period times, 6 months (IQR 4-8) before the CRC diagnosis and at the time of the diagnosis. ROC analysis was performed to evaluate the discriminatory accuracy of each index and we calculated Se, Sp, PPV, NPV, and OR to identify the diagnostic performance of each positive marker.

RESULTS

NP/LHb showed high Sp (92.06%) and PPV (87.50%) to diagnose patients with CRC. This index exhibited an OR of 14.52 (8.26-25.52) and the best area under the curve (AUC: 0.78) for a positive CRC diagnosis. We found significant differences in all indices according to the presence of CRC, observing the highest values in CRC patients at time of diagnosis, in comparison with the analysis performed in the previous months to diagnosis or with control patients. There were significant differences in all ratios according to TNM stages ( < 0.05). PLR, SII and NP/LHb (but not NLR) showed significant differences according to tumor location ( < 0.05). Right-sided colon cancers presented the highest values, in comparison with left-sided and rectal cancers.

CONCLUSIONS

Systemic inflammatory cell ratios (especially NP/LHb) change over time with the development of CRC, so they could be useful in its early diagnosis. We suggest that they could be routinely measured in patients with suspicion of CRC, to identify those ones with a higher risk of cancer, considering the high positive predictive value they have shown in our study.

摘要

背景

全身炎症似乎参与了结直肠癌(CRC)的发病机制。反映炎症状态的分析标志物,如中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)或全身免疫炎症指数(SII),已被提议作为CRC预后的工具。然而,它们在诊断中的应用鲜有研究。

目的

分析这些标志物以及一种将SII与血红蛋白浓度相结合的新标志物NP/LHb = [中性粒细胞×血小板]/[淋巴细胞×血红蛋白]作为CRC诊断工具的能力。此外,我们研究了它们与CRC相关变量的关联。

方法

病例对照研究,纳入214例CRC患者和214例无CRC的对照者,按年龄(±5岁)和性别匹配。我们收集了人口统计学、CRC相关和实验室变量,以计算NLR、PLR、SII和NP/LHb。在病例组中,实验室变量在CRC诊断前6个月(四分位间距4 - 8)和诊断时两个不同时间段收集。进行ROC分析以评估每个指标的鉴别准确性,并计算敏感性(Se)、特异性(Sp)、阳性预测值(PPV)、阴性预测值(NPV)和比值比(OR),以确定每个阳性标志物的诊断性能。

结果

NP/LHb在诊断CRC患者时显示出高特异性(92.06%)和阳性预测值(87.50%)。该指标的比值比为14.52(8.26 - 25.52),在CRC阳性诊断时曲线下面积最大(AUC:0.78)。根据是否存在CRC,我们发现所有指标均有显著差异,与诊断前几个月或对照患者的分析相比,CRC患者在诊断时各项指标值最高。根据TNM分期,所有比值均有显著差异(P < 0.05)。根据肿瘤位置,PLR、SII和NP/LHb(但不包括NLR)有显著差异(P < 0.05)。与左侧结肠癌和直肠癌相比,右侧结肠癌的各项指标值最高。

结论

随着CRC的发展,全身炎症细胞比值(尤其是NP/LHb)随时间变化,因此它们可能有助于早期诊断。考虑到它们在我们研究中显示出的高阳性预测值,我们建议对疑似CRC的患者进行常规检测,以识别那些癌症风险较高的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9429/9252519/477cb2063ea9/fmed-09-843074-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验